A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs
The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.
Read original article on Inc.com →Related news
-
REA Reverse – Engineer Anything
-
Has the Autonomous Trucking Revolution Arrived?
- 11 of 23 Core Open Source Projects Run on 1 or 2 People
- The logarithms of rational numbers have irrationality exponent 2 [pdf]
-
Step-by-Step Guide to Migrate Applications to the Cloud
- Compiling Rust to readable C with Eurydice
-
5 Key Strategies for Effectively Supervising Remote Employees
-
Rewriting Prime Agent in Rust